HIF2α inhibitor provides significant clinical benefit in patients with VHL kidney cancer

One of the major breakthroughs this year the hypoxia-inducible factor (HIF)-2α inhibitor: MK6482 for von Hippel-Lindau (VHL) disease–related clear cell renal cell carcinoma (RCC). VHL disease is a hereditary disease that affects many organs of the body, such as the eyes, brain, spine, pancreas, kidneys and lymphatic system. It is caused by a mutation in […]

read more

Managing adverse events in kidney cancer patients on immunotherapy/TKI combination treatment

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center, Texas in the USA talks about managing adverse events to immunotherapy and targeted therapy combinations. There are more adverse events from any type of combination treatment compared to single treatments, especially immune adverse events. Nivolumab alone is very well tolerated and quite easy […]

read more

Cabozantinib plus atezolizumab for non-clear cell kidney cancer

In this video interview, Dr Monty Pal from the City of Hope Hospital in California talks about a subset of patients in the COSMIC-021 (cohort 10) with non-clear cell RCC, such as papillary renal cell carcinoma (RCC) and chromophobe RCC. Response rates exceeded 30%, which are very promising findings compared to TKIs alone. However, not […]

read more

Managing immune-related adverse events

In these video interviews, Dr Eric Jonasch from MD Anderson Cancer Center in Texas and Dr Monty Pal from the City of Hope Hospital in California talk about immune-related adverse events in people with advanced kidney cancer taking combination therapies and immunotherapy: Managing Adverse Events Among RCC Patients Receiving Combination Treatment With Targeted Therapy and […]

read more

Probiotic supplements and improves clinical benefit in kidney cancer

This prospective, randomised study in 20 people looked at the ability of probiotic supplements to modify the clinical benefit of targeted therapy (VEGF-TKIs cabozantinib or sunitinib) in metastatic renal cell carcinoma patients. The study showed that in people with metastatic RCC, the clinical benefit rate was similar in people taking probiotics compared to those who […]

read more

Lenvatinib plus everolimus for non clear cell kidney cancer

Treating non-clear cell renal cell carcinoma (RCC) is challenging because these diseases are rare, and so far there are no effective treatments for this group of patients. Non-clear cell RCC is currently treated in a similar way to clear cell RCC. In a phase 2 clinical trial, 31 patients with non-clear cell RCC were treated […]

read more

Differences in survival with tremelimumab due to different types of kidney cancer

Most people have a type of kidney cancer called clear cell renal cell carcinoma (RCC). A recent study has shown that people with clear cell RCC have a better response to tremelimumab (an anti-CTLA-4 antibody) compared with patients with non-clear cell RCC following a procedure called cryoablation (freezing the tumour using probes through the skin). […]

read more

Future for VHL kidney cancer is bright

Von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) has always been difficult to treat. However, a group of researchers led by Dr William G. Kaelin Jr from the Dana-Faber Cancer Institute and Harvard Medical School in America have discovered treatments including immunotherapy, HIF-2α inhibitors, and potentially CDK4/6 inhibitors for the treatment of VHL-associated RCC. He […]

read more

Nephritis as a potential predictor of response to immune checkpoint inhibitors in kidney cancer

This study, to be published in Journal for Immunotherapy of Cancer, looks at the immune-related adverse event, acute interstitial nephritis (inflammation of the kidney tissues), as a biomarker for response to immune checkpoint inhibitors. Using a database, the researchers identified 177 patients with metastatic renal cell carcinoma (RCC) who received at least one dose of […]

read more

γ-Glutamyltransferase as a biomarker in patients on nivolumab for metastatic kidney cacner

A protein called γ-glutamyltransferase can predict survival in patients with local and metastatic renal cell carcinoma (RCC); however, in patients treated with immune checkpoint inhibitors, such as nivolumab, this predictive role is unknown. A study to be published in the International Journal of Clinical Oncology aimed to investigate the role of γ-glutamyltransferase as a predictive […]

read more
Showing 1 to 10 of 711 results
  TOP